Dietary vs. Meso-zeaxanthin

Orange Paprika Pepper

Are dietary zeaxanthin and meso-zeaxanthin the same?

 

  1. Dietary zeaxanthin and meso-zeaxanthin are different ingredients. Unlike dietary Zeaxanthin, meso-zeaxanthin is a synthetic ingredient.
  2.  

  3. Dietary zeaxanthin contained in EyePromise supplements is derived from orange paprika peppers grown and processed in the USA. Meso-zeaxanthin is not found in the U.S. daily diet but instead created from a harsh chemical modification of a crude marigold extract.
  4.  

  5. The landmark AREDS 2 clinical research study1 evaluated lutein, dietary zeaxanthin, zinc, omega 3s, vitamin C, E, and copper in 4,203 subjects with intermediate or advanced AMD. Meso-zeaxanthin was not evaluated in this study.
  6.  

  7. The Zeaxanthin and Visual Function Study2 demonstrated a robust macular pigment optical density increase and visual function improvements following supplementation of 8mg of dietary zeaxanthin daily for 12 months in elderly subjects. No meso-zeaxanthin publications exist that demonstrate it has been tested by itself without other carotenoids, so any beneficial effects are unknown. This is also true regarding whether Macular Pigment Optical Density (MPOD) can actually be increased by meso-zeaxanthin alone.
     
    Results: “In the zeaxanthin group, detailed high-contrast visual acuity improved by 1.5 lines, Retina Foundation of the Southwest shape discrimination sharpened from 0.97 to 0.57 (P = 0.06, 1- tail), and a larger percentage of zeaxanthin patients experienced clearing of their KVF central scotomas (P = 0.057)”
  8.  

  9. 3-4 human meso-zeaxanthin supplementation reports concur that there is poor uptake of meso-zeaxanthin into the blood.
  10.  

  11. Meso-zeaxanthin is currently imported from a group of suppliers in India, China, and Mexico – none of which have FDA oversight.

 
1. Lutein +Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration The Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial

Author: Emily Y. Chew, MD, National Eye Institute, National Institutes of Health, Bldg 10, CRC Room 3-2531, 10 Center Dr, MSC 1204, Bethesda, MD 20892-1204 (echew@nei.nih.gov).

JAMA. 2013;309(19):doi:10.1001/jama.2013.4997

2. Randomized, double-blind, placebo-controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration
The Zeaxanthin and Visual Function Study (ZVF)
FDA IND #78, 973

Stuart P. Richer, O.D., Ph.D.,a,b William Stiles, M.D., J.D.,a Kelly Graham-Hoffman, PsyD,a Marc Levin, M.D., J.D.,a Dennis Ruskin, O.D.,c James Wrobel, DPM,b Dong-Wouk Park,b and Carla Thomasa

aCaptain James A. Lovell Federal Health Care Facility, North Chicago, Illinois; bRosalind Franklin University of Medicine and Science, Chicago Medical School, North Chicago, Illinois; and cPrivate Practice, Toronto, Canada.

Optometry (2011) 82, 667-680

View our scientific support. For additional questions, contact EyePromise at
support@eyepromise.com
or call 1-866-833-2800.